Prescribed Health Apps Market to Gather Momentum with Increased Investor Backing :

Pune, India, May 2019, MRFR Press Release/- Market Research Future has Published a Half-Cooked Research Report on the Global Prescribed Health Apps Market.  

Market Overview

The penetration of technology in healthcare has created a very broad base for the growth of prescribed health apps. Reports that gauge the healthcare IT industry has been made available by Market Research Future which creates reports on several industry verticals that review the market growth and prospects. The market is expected to chart an upward growth trajectory with a favorable CAGR in the impending period.

The development of the market for prescribed health apps is anticipated to be motivated by the seamless connectivity established between the patients and the healthcare provider. The ease of accessibility to emergency and important medical information is expected to further increase the penetration of the prescribed health apps in the end user base around the globe. The prevalent trend for health monitoring is expected to influence the market progress deeply in the forecast period.

Segmental Analysis

The segmental evaluation of the prescribed health apps market is conducted on the basis of the operating system, devices, and region. On the basis of the operating system, the prescribed health apps market is segmented into Androids, Windows, and iPhones. Based on the devices, the prescribed health apps market is segmented into multi-parameter tracker, diabetes management device and cardiac monitoring device. On the basis of regions, the prescribed health apps market is segmented into the Middle East, Asia Pacific, Americas, Europe and Africa.

Access Report Details @

Competitive Analysis

The advancement of the market is projected to capture amplified impetus in the coming years chiefly due to the incidence of contributory government plans. The escalated turnaround in the market is likely to set off new openings for the development of the market. The enhancement in different domestic economies is projected to encourage the progress of the market in the impending period. The ease in accessing key planned opportunities important to consequent stabilization of inflation is projected to generate a promising option for development in the approaching years. In the approaching years, the control exerted by fairly high-income level nations around the world and the likely gains observed towards a few of the currencies around the world is projected to strengthen the fruition of the market in the forecast period. A significant climb in the number of backers in the market is expected to craft an advantageous state of affairs for the evolution of the market in the projected period.

The central competitors shaping the prescribed health apps market globally are Apple, iHealth Lab, Inc. BioTelemetry Inc. Sanofi, AirStrip Technologies, Inc, LifeWatch AG among others.


Regional Analysis


The regional study of the prescribed health apps market covers regions such as the Middle East, Asia Pacific, Americas, Europe and Africa. As per the analysis, the North America region is the top market for health apps. The North American region leads the domain of healthcare information technology, i.e. digital health or eHealth. The technology development in electronic health to smartphones apps in the medical field has augmented the market’s prospect for personal healthcare apps. Moreover, the time taken to expand and upgrade the applications has created more reasons to make certain that the designed phase is optimized fully. The European region is also presenting high growth in the prescribed health apps market. The European nations such as Germany and the UK are countries are increasingly investing in health apps. Thus, the European region is expected to play an important role in the expansion of the prescribed health apps market in the upcoming period.

Industry Updates

  • Mar 2019 A Seattle-based digital prescribing platform, Xealth, has successfully raised USD 11 million in Series A funding from Novartis, McKesson Ventures, Philips, and ResMed. The existing investors are UPMC and Froedtert, Providence Ventures, Threshold Ventures, and the Medical College of Wisconsin health network which had also participated in the funding round.
  • Jan 2019 Otsuka is planning on working together with Click Therapeutics to develop and commercialize a ‘prescription digital therapeutic’ for major depressive disorder (MDD). Otsuka will assign capital to entirely fund the growth of Click’s mobile app ‘CT-152’ for MDD, and to commercialize it globally upon attainment of regulatory approvals.